Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Guberina M, Pöttgen C, Guberina N, Hoffmann C, Wiesweg M, Richlitzki C, Metzenmacher M, Aigner C, Bölükbas S, Gauler T, Eberhardt WEE, Forsting M, Herrmann K, Theegarten D, Darwiche K, Jendrossek V, Stuschke M, Schuler M. Guberina M, et al. Among authors: pottgen c. Cancers (Basel). 2024 Mar 17;16(6):1174. doi: 10.3390/cancers16061174. Cancers (Basel). 2024. PMID: 38539510 Free PMC article.
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Guberina M, Guberina N, Pöttgen C, Gauler T, Richlitzki C, Metzenmacher M, Wiesweg M, Plönes T, Forsting M, Wetter A, Herrmann K, Hautzel H, Darwiche K, Theegarten D, Aigner C, Schuler M, Stuschke M, Eberhardt WE. Guberina M, et al. Among authors: pottgen c. Immunotherapy. 2022 Aug;14(12):927-944. doi: 10.2217/imt-2021-0341. Epub 2022 Jul 13. Immunotherapy. 2022. PMID: 35822656 Free article. Clinical Trial.
Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment.
Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, Metzenmacher M, Theegarten D, Gauler T, Darwiche K, Aigner C, Eberhardt WEE, Stuschke M. Guberina N, et al. Among authors: pottgen c. Radiat Oncol. 2022 Jul 16;17(1):126. doi: 10.1186/s13014-022-02080-9. Radiat Oncol. 2022. PMID: 35842712 Free PMC article.
Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis.
Guberina N, Padeberg F, Pöttgen C, Guberina M, Lazaridis L, Jabbarli R, Deuschl C, Herrmann K, Blau T, Wrede KH, Keyvani K, Scheffler B, Hense J, Layer JP, Glas M, Sure U, Stuschke M. Guberina N, et al. Among authors: pottgen c. Cancers (Basel). 2023 May 30;15(11):2982. doi: 10.3390/cancers15112982. Cancers (Basel). 2023. PMID: 37296942 Free PMC article.
Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation.
Pöttgen C, Eberhardt W, Graupner B, Theegarten D, Gauler T, Freitag L, Abu Jawad J, Wohlschlaeger J, Welter S, Stamatis G, Stuschke M. Pöttgen C, et al. Eur J Cancer. 2013 Jun;49(9):2107-15. doi: 10.1016/j.ejca.2013.02.030. Epub 2013 Mar 16. Eur J Cancer. 2013. PMID: 23510803
125 results